IL247246A0 - proteins fc multimers - Google Patents

proteins fc multimers

Info

Publication number
IL247246A0
IL247246A0 IL247246A IL24724616A IL247246A0 IL 247246 A0 IL247246 A0 IL 247246A0 IL 247246 A IL247246 A IL 247246A IL 24724616 A IL24724616 A IL 24724616A IL 247246 A0 IL247246 A0 IL 247246A0
Authority
IL
Israel
Prior art keywords
multimeric
proteins
Prior art date
Application number
IL247246A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201403915A external-priority patent/GB201403915D0/en
Priority claimed from GB201403914A external-priority patent/GB201403914D0/en
Priority claimed from GBGB1405955.4A external-priority patent/GB201405955D0/en
Priority claimed from GB201412648A external-priority patent/GB201412648D0/en
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of IL247246A0 publication Critical patent/IL247246A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL247246A 2014-03-05 2016-08-11 proteins fc multimers IL247246A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201403915A GB201403915D0 (en) 2014-03-05 2014-03-05 Proteins
GB201403914A GB201403914D0 (en) 2014-03-05 2014-03-05 Proteins
GBGB1405955.4A GB201405955D0 (en) 2014-04-02 2014-04-02 Proteins
GB201412648A GB201412648D0 (en) 2014-07-16 2014-07-16 Proteins
PCT/EP2015/054688 WO2015132365A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (1)

Publication Number Publication Date
IL247246A0 true IL247246A0 (en) 2016-09-29

Family

ID=52697365

Family Applications (1)

Application Number Title Priority Date Filing Date
IL247246A IL247246A0 (en) 2014-03-05 2016-08-11 proteins fc multimers

Country Status (13)

Country Link
US (1) US20170081406A1 (https=)
EP (1) EP3114137A1 (https=)
JP (1) JP6851199B2 (https=)
KR (1) KR20160127821A (https=)
CN (1) CN106132994A (https=)
AU (1) AU2015226101B2 (https=)
BR (1) BR112016020377A2 (https=)
CA (1) CA2939201A1 (https=)
IL (1) IL247246A0 (https=)
MX (1) MX2016010953A (https=)
RU (1) RU2016139022A (https=)
SG (1) SG11201606596PA (https=)
WO (1) WO2015132365A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
JP2017518965A (ja) 2014-05-02 2017-07-13 モメンタ ファーマシューティカルズ インコーポレイテッ エンジニアリングされたＦｃ構築物に関連する組成物および方法
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
LT3325011T (lt) 2015-07-24 2021-01-25 Gliknik Inc. Iš žmogaus baltymo fragmentų sulieti baltymai, siekiant sukurti tvarkingai multimerizuoto imunoglobulino fc kompozicijas su padidintu komplemento surišimu
EP3408279A1 (en) * 2016-01-27 2018-12-05 CSL Behring Lengnau AG Recombinant igg fc multimers
WO2017151971A2 (en) 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
BR112018074056A2 (pt) 2016-05-23 2019-03-06 Momenta Pharmaceuticals, Inc. composições e métodos relacionados a construtos de fc manipulados
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
AU2017300794A1 (en) 2016-07-22 2019-01-24 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
WO2018183520A1 (en) * 2017-03-28 2018-10-04 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
EP3723791B1 (en) * 2017-12-14 2024-02-21 CSL Behring Lengnau AG Recombinant igg fc multimers for the treatment of neuromyelitis optica
CN113271972B (zh) 2018-11-14 2025-06-17 Jn生物科学有限责任公司 用于替代IVIG的多聚体杂交Fc蛋白
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
CN114401985A (zh) 2019-09-13 2022-04-26 康诺贝林伦瑙有限公司 用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体
WO2021111007A1 (en) * 2019-12-06 2021-06-10 CSL Behring Lengnau AG Stable compositions of fc multimers
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体
CN120060370A (zh) * 2023-11-29 2025-05-30 上海科锐克医药科技有限公司 用于递送人vegf受体融合蛋白的基因递送载体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160855T1 (hr) * 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
ES2610327T3 (es) * 2008-03-13 2017-04-27 Biotest Ag Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
EP2389192A4 (en) * 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
JP6205363B2 (ja) * 2011-09-26 2017-09-27 ジェイエヌ バイオサイエンシーズ エルエルシー ハイブリッド定常領域
CN104684928A (zh) * 2012-08-02 2015-06-03 Jn生物科学有限责任公司 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白

Also Published As

Publication number Publication date
WO2015132365A1 (en) 2015-09-11
CA2939201A1 (en) 2015-09-11
RU2016139022A (ru) 2018-04-25
AU2015226101A1 (en) 2016-08-25
CN106132994A (zh) 2016-11-16
JP6851199B2 (ja) 2021-03-31
US20170081406A1 (en) 2017-03-23
BR112016020377A2 (pt) 2018-01-23
SG11201606596PA (en) 2016-09-29
JP2017509335A (ja) 2017-04-06
EP3114137A1 (en) 2017-01-11
KR20160127821A (ko) 2016-11-04
AU2015226101B2 (en) 2019-08-22
MX2016010953A (es) 2016-11-29

Similar Documents

Publication Publication Date Title
IL247096A0 (en) proteins fc multimers
IL247246A0 (en) proteins fc multimers
IL246355B (en) p97–ids fused proteins
GB201415344D0 (en) Protein
GB201418562D0 (en) Peptides
HUE067090T2 (hu) Fehérje
HUE057808T2 (hu) Fehérje visszanyerés
ZA201606327B (en) Uti fusion proteins
IL248276A0 (en) Carbohydrate binding proteins
SG11201606501PA (en) Nanobody-fluorescent protein fusion
PL3099793T3 (pl) Białko
GB201401877D0 (en) Peptides
EP3099320A4 (en) Protein m related immunoglobulin-binding polypeptides
EP3204427A4 (en) Chimeric proteins
GB201517390D0 (en) Protein variant analysis
GB201410686D0 (en) Peptides
GB201412797D0 (en) Proteins
GB201412648D0 (en) Proteins
GB201412646D0 (en) Proteins
GB201412649D0 (en) Proteins
GB201406894D0 (en) Proteins
GB201405952D0 (en) Proteins
GB201405955D0 (en) Proteins
GB201403915D0 (en) Proteins
GB201403913D0 (en) Proteins